Both coprimary endpoints were met, supporting that [18F]CTT1057 can be added to the armamentarium of PSMA-targeted PET tracers, thus increasing patient access to proper diagnosis and tailored PCa treatment. This evidence concerns the gene FOLH1 and posterior cortical atrophy.